Vaxart (VXRT) Scheduled to Post Earnings on Monday

Vaxart (NASDAQ:VXRT) is set to issue its quarterly earnings data after the market closes on Monday, May 13th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter.

Vaxart (NASDAQ:VXRT) last issued its quarterly earnings data on Thursday, March 14th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.03. Vaxart had a negative net margin of 1,117.56% and a negative return on equity of 108.45%. The firm had revenue of $3.25 million during the quarter, compared to the consensus estimate of $0.45 million. On average, analysts expect Vaxart to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Vaxart Trading Down 1.1 %

Vaxart stock opened at $0.73 on Wednesday. Vaxart has a 12 month low of $0.53 and a 12 month high of $1.59. The company has a market capitalization of $129.09 million, a price-to-earnings ratio of -1.27 and a beta of 0.72. The stock’s 50 day moving average is $1.03 and its 200-day moving average is $0.89.

Analysts Set New Price Targets

Separately, B. Riley upgraded shares of Vaxart from a “neutral” rating to a “buy” rating and set a $2.00 price objective for the company in a research note on Wednesday, January 31st.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.